Intertek Group PLC
15 May 2006
15 May 2006, 2pm (UK)
Intertek Group plc ('Intertek')
Intertek in discussions on an outsourcing deal with Chemelot
Intertek, the international provider of quality and safety services to a wide
range of industries, announces that its Oil, Chemical and Agri division is
currently in discussions with Chemelot BV on the outsourcing of an analytical
chemical testing laboratory in Geleen, Netherlands. Chemelot BV is a subsidiary
of DSM N.V. Consultations have commenced with the works council and trade unions
as provided for by European Union and Dutch law.
A further announcement relating to this outsourcing contract will be made in due
course.
ABOUT INTERTEK
Intertek is a leading international provider of quality and safety services to a
wide range of global and local industries. Partnership with Intertek brings
increased value to customers' products, processes and ultimately supports their
success in the global market place. Intertek has the experience, expertise,
resources and global reach to support their customers through their network of
over 850 laboratories and offices, 15,500 people in more than 100 countries
around the world.
ABOUT CHEMELOT
In the field of investments for the chemical industry Chemelot is an important
business partner in Western Europe. Furthermore Chemelot is an innovative
chemical community, with an excellent infrastructure and perfect logistics via
water, rail and road. The Chemelot community in Geleen has all ingredients for
so called accelerated business growth, driven by new investments in research
activities; all kind of new start-ups and an innovative open campus. In many
different ways Chemelot has a high added value in realizing innovative plans and
investments in chemical activities.
ABOUT DSM
DSM is active worldwide in nutritional and pharma ingredients, performance
materials and industrial chemicals. The company creates innovative products and
services that help improve the quality of life. DSM's products are used in a
wide range of end markets and applications such as human and animal nutrition
and health, cosmetics, pharmaceuticals, automotive and transport, coatings,
housing and electrics & electronics (E&E). DSM's strategy, named Vision 2010 -
Building on Strengths, focuses on accelerating profitable and innovative growth
of the company's specialties portfolio. Market-driven growth, innovation and
increased presence in emerging economies are key drivers of this strategy. The
group has annual sales of over EUR 8 billion and employs some 22,000 people
worldwide. DSM ranks among the global leaders in many of its fields. The company
is headquartered in the Netherlands, with locations in Europe, Asia, Africa and
the Americas.
ENQUIRIES:
INTERTEK
Aston Swift, Investor Relations Intertek
Telephone: +44 (0) 20 7396 3400
Aston.swift@intertek.com
Richard Mountain, Financial Dynamics
Telephone: +44 (0) 20 7831 3113
Richard.mountain@fd.com
Internet: www.intertek.com
High-resolution images of Intertek Group plc businesses are available to
download, free of charge from www.vismedia.co.uk.
CHEMELOT AND DSM
Gerard van der Zanden, Communications Chemelot and DSM
Telephone: +31 (0) 46 47 64077
Gerard.zanden-van-der@dsm.com
Internet: www.chemelot.nl and www.dsm.com
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.